Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1931 • ACR Convergence 2021
The Burden of Thirty-day Readmission and Independent Predictors of Readmission in Patients with Systemic Lupus Erythematosus: A Nationwide Analysis
Ashu Acharya¹, Saffa Iftikhar¹, Yasmin Khader¹, Sachit Sharma¹, Joan N Gekonde¹, Rawish Fatima¹, Cameron J Burmeister¹ and Nezam Altorok², ¹University of Toledo Medical Center, Toledo, OH, ²University of Toledo, Toledo, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic immune-mediated disease with 20-25% patients needing hospital admission annually. Early readmissions add to the clinical and economic…
Abstract Number: 0006 • ACR Convergence 2021
Metabolic Characteristics of Age-related B Cells in Lupus-prone Mice and Effects on Follicular Helper T Cells
Ivan Ramirez¹, Betty Diamond² and Sun Jung Kim³, ¹Northwell, Little Neck, NY, ²Northwell Health, Manhasset, NY, ³Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Since the description of age-associated B cells (ABC), there has been a growing interest in the role of these cells in autoimmunity. Evidence suggests…
Abstract Number: 0233 • ACR Convergence 2021
Feasibility and Acceptability of an Online Intervention for Lupus Self-Management Based on the Transtheoretical Model of Change
Katherine Carpenter¹, Melissa French¹, Sara Balestrieri², Sara Johnson², Sarah Gilman³, Cristina Drenkard⁴, S Sam Lim⁵, Maria Dall'Era⁶, Emily Somers⁷, Suzanna Zick⁸, Victoria Werth⁹, Daniel Wallace¹⁰, Melicent Miller¹ and Mary Crimmings¹, ¹Lupus Foundation of America, Washington, DC, ²Pro-Change Behavior Systems, South Kingstown, RI, ³Wayfinder Health Strategies, Falls Church, VA, ⁴Emory University, Atlanta, GA, ⁵Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁶University of California San Francisco, Corte Madera, CA, ⁷University of Michigan, Ann Arbor, MI, ⁸Department of Family Medicine and Nutritional Sciences, Ann Arbor, MI, ⁹Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ¹⁰Cedars-Sinai, Los Angeles, CA
Background/Purpose: The Lupus Foundation of America (LFA) has completed a 5-year cooperative agreement with the CDC to develop and evaluate an online lupus self-management (SM)…
Abstract Number: 0337 • ACR Convergence 2021
Rarity of Pneumocystis Jirovecii Pneumonia in Patients with Systemic Lupus Erythematosus Using a Real-world, Electronic Health Record
Ben Boone and April Barnado, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Infection is the leading cause of mortality and one of the most common causes of hospitalization in patients with systemic lupus erythematosus (SLE). Pneumocystis…
Abstract Number: 0456 • ACR Convergence 2021
Functional Connectivity, Enhanced Blood-Brain Barrier Leakage and Cognitive Impairment in Systemic Lupus Erythematosus
John Hanly¹, Jason Robertson¹, Lyna Kamintsky¹, Alon Friedman¹, Steven Beyea¹, John Fisk¹, Antonina Omisade¹, Cindy Calkin¹, Tim Bardouille¹, Chris Bowen¹, Alexandra Legge¹, Arnold Mitnitski², Kara Matheson² and Javeria Hashmi¹, ¹Dalhousie University, Halifax, NS, Canada, ²Nova Scotia Health Authority, Halifax, NS, Canada
Background/Purpose: Cognitive impairment is the most frequent manifestation of neuropsychiatric systemic lupus erythematosus (NPSLE), yet the mechanisms underlying it remain poorly understood. We have previously…
Abstract Number: 0594 • ACR Convergence 2021
The Burden of Systemic Lupus in Five Distinct Racial and Ethnic Groups in Israel: A Population-based Study
Titilola Falasinnu¹, Nada Rizk¹, Becca Feldman², Devy Zisman³, Michael Leshchinsky², Gabriella Lawrence², Yashaar Chaichian⁴ and Julia Simard¹, ¹Stanford School of Medicine, Stanford, CA, ²Clalit Research Institute, Clalit Health Services, Ramat Gan, Israel, ³Carmel Medical Center, Haifa, Israel, ⁴Stanford University, Los Gatos, CA
Background/Purpose: Misclassification of race and ethnicity in data can impact how disparities in prevalence, incidence, severity, and complications of systemic lupus erythematosus (SLE) are interpreted.…
Abstract Number: 0637 • ACR Convergence 2021
Assessing the Rates of Cervical Cancer Screening in Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Tara Skorupa¹, Sonia Khatter², Alana Freifeld¹ and Elena Weinstein³, ¹University of Colorado, Denver, CO, ²University of Colorado, Aurora, CO, ³University of Colorado, Englewood, CO
Background/Purpose: Prior studies have described increased incidence of cervical dysplasia and cervical cancer in women with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), suggesting…
Abstract Number: 0861 • ACR Convergence 2021
Systemic Lupus Erythematosus, a Pilot Study of a New Disease Activity Score
Daphna Paran¹, Monique Ben-Am², Liran Mendel², Ari Polachek³, Victoria Furer², Ofir Elalouf⁴, Jonathan Wollman⁴, Shaye Kivity⁵ and Nancy Agmon-Levin⁶, ¹Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel, ²Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Sourasky Medical Center, Petah-Tikva, Israel, ⁴Tel Aviv Medical Center, Herzliya, Israel, ⁵Meir Medical Center, Kefar Saba, Israel, ⁶Sheba Medical Center, Ramat Gan, Israel
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous, waxing and waning, multisystem autoimmune disease. The complexity and clinical unpredictability of SLE challenge the assessment of…
Abstract Number: 0878 • ACR Convergence 2021
Investigating the Neutrophil to Lymphocyte Ratio as a Marker of SLE Disease Activity, Health-Related Quality of Life and Depression
Eleni Papachristodoulou¹, Loukas Kakoullis¹, Savvas Psarelis², Victor Hajiroussos³, Costas Christophi⁴ and Konstantinos Parperis¹, ¹University of Cyprus Medical School, Nicosia, Cyprus, ²Nicosia General Hospital/University of Cyprus Medical Schooll, Nicosia, Cyprus, ³Ygia Polyclinic Hospital, Limassol, Cyprus, ⁴Cyprus University of Technology, Limassol, Cyprus
Background/Purpose: The need for readily available markers of SLE activity has led to the evaluation of laboratory parameters, such as the neutrophil to lymphocyte ratio…
Abstract Number: 0896 • ACR Convergence 2021
Systemic Lupus Erythematosus Disease Flares After SARS-CoV-2 Vaccination
Medha Barbhaiya¹, Jonah Levine¹, Caroline Siegel¹, Vivian Bykerk², Deanna Jannat-Khah¹ and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Hospital for Special Surgery, New York City, NY
Background/Purpose: Vaccination against SARS-CoV-2 is particularly important for patients with systemic lupus erythematosus (SLE), who may be at increased risk of hospitalization for COVID-19. However,…
Abstract Number: 1047 • ACR Convergence 2021
Exposure to Industrial Pollutants and Mortality Due to Inmune-mediated Inflammatory Systemic Diseases (IMD) in Spain
ana Perez¹, Arturo Rodriguez Pérez², Pablo Fernandez-Navarro³, Fernando Albarran⁴, Cristina Bohorquez⁴, Atusa Movasat⁴, Lucia Ruiz⁴, Paula Pretel⁴, elena Rabadan⁴, Valentina Emperiale⁴, Adrian abbasi⁵, julio suarez⁵, Lorena Montano⁴, emilio rico⁵, alfredo prieto², melchor Alvarez de Mon⁵ and beatriz perez³, ¹Hospital Universitario Príncipe de Asturias. Rheumatology. Medicine Faculty. Alcala University Department., Madrid, Spain, ²Faculty of Medicine. Alcala University, Alcala de Henares, Spain, ³Department of Epidemiology of Chronic Diseases.National Center of Epidemiology/CIBERESP. Instituto de Salud Carlos III, Madrid, Spain, ⁴Hospital Universitario Príncipe de Asturias, Rheumatology Department, Alcala de Henares, ⁵Hospital Universitario Príncipe de Asturias, Madrid, Spain
Background/Purpose: The etiology of many IMD is largely unknown; however, available data suggest that environmental contaminants could play a role in their origin. Industrial facilities…
Abstract Number: 1259 • ACR Convergence 2021
Association of SLE Responder Index (SRI) Attainment and Long-term Clinical Outcomes
Kathryn Connelly¹, Rangi Kandane-Rathnayake¹, Alberta Hoi², Worawit Louthrenoo³, Laniyati Hamijoyo⁴, Jiacai Cho⁵, Aisha Lateef⁶, Shue-Fen Luo⁷, Yeong-Jian Wu⁸, C.S. Lau⁹, YI-HSING CHEN¹⁰, Sandra Navarra¹¹, Leonid Zamora¹¹, Zhanguo Li¹², Yuan An¹², Sargunan Sockalingam¹³, Yanjie Hao¹⁴, Zhuoli Zhang¹⁴, Madelynn Chan¹⁵, Yasuhiro Katsumata¹⁶, Masayoshi Harigai¹⁶, Shereen Oon¹⁷, Sang-Cheol Bae¹⁸, Sean O’Neill¹⁹, Kathryn Gibson¹⁹, Jun Kikuchi²⁰, B.M.D.B. Basnayake²¹, Tsutomu Takeuchi²², Kristine (Pek Ling) Ng²³, Fiona Goldblatt²⁴, Annie Law²⁵, Nicola Tugnet²⁶, Yoshiya Tanaka²⁷, Sunil Kumar²⁸, Michael Tee²⁹, Jin Yu Tan³⁰, Chetan Karyekar³¹, Mandana Nikpour³², Vera Golder¹ and Eric Morand³³, ¹Monash University, Clayton, Australia, ²Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia, ³Maharaj Nakorn Chiangmai, Chiang Mai, Thailand, ⁴University of Padjadjaran, Bandung, Indonesia, ⁵National University Health System (NUHS), Singapore, Singapore, ⁶National University Hospital, Singapore, Singapore, ⁷Chang Gung Memorial Hospital, Taipei, Taiwan, ⁸Chang Gung Memorial Hospital, Taoyuan County, Taiwan, ⁹University of Hong Kong, Hong Kong, Hong Kong, ¹⁰Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ¹¹University of Santo Tomas Hospital, Manila, Philippines, ¹²People's Hospital, Peking University Health Science Center, Beijing, China (People's Republic), ¹³University of Malaya, Kuala Lumpur, Malaysia, ¹⁴Peking University First Hospital, Beijing, China (People's Republic), ¹⁵Tan Tock Seng Hospital, Singapore, Singapore, ¹⁶Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ¹⁷Melbourne Health, Parkville, Australia, ¹⁸Hanyang University Medical Center, Seoul, Republic of Korea, ¹⁹Liverpool Hospital, Sydney, Australia, ²⁰Keio University School of Medicine, Tokyo, Japan, ²¹Teaching (General) Hospital, Kandy, Sri Lanka, ²²Div. Rheumatology, Keio University, Tokyo, Japan, ²³North Shore Hospital, Auckland, New Zealand, ²⁴Flinders Medical Centre, Adelaide, Australia, ²⁵Singhealth, Singapore, Singapore, ²⁶Auckland District Health Board, Auckland, New Zealand, ²⁷University of Occupational and Environmental Health, Kitakyushu, Japan, ²⁸Counties Manukau Health, Auckland, New Zealand, ²⁹University of the Philippines, Quezon City, Philippines, ³⁰Janssen Asia Pacific, Singapore, Singapore, ³¹Janssen R&D, Spring House, PA, ³²University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ³³School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia
Background/Purpose: The SLE Responder Index (SRI) is a composite responder definition employed as a clinical trial endpoint in SLE. Despite its widespread adoption, recent discrepant…
Abstract Number: 1275 • ACR Convergence 2021
Digital Solution for Collection of Patient-reported Outcome Measures in Patients with Systemic Lupus Erythematosus: A Randomised, Crossover, Agreement Study
Line Uhrenholt¹, Simone Høstgaard², Julie Pedersen², Robin Christensen³, Lene Dreyer¹, Henrik Leffers⁴, Peter C Taylor⁵, Vibeke Strand⁶, Sren Jacobsen⁴, Anne Voss⁷, Jon Gregersen⁸ and Salome Kristensen¹, ¹Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ²Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, ³Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen & Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Copenhagen, Denmark, ⁴Copenhagen Lupus and Vasculitis Clinic, Centre for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ⁵University of Oxford, Oxford, United Kingdom, ⁶Stanford University School of Medicine, Portola Valley, CA, ⁷Department of Rheumatology, Odense University Hospital, Odense C, Denmark, ⁸Department of Nephrology, Aalborg University Hospital, Aalborg, Denmark, Aalborg, Denmark
Background/Purpose: Patient-reported outcome measures (PROMs) provide the physician with an important insight into the patients’ perception of lupus disease activity. Technology and the widespread use…
Abstract Number: 1291 • ACR Convergence 2021
Risk of Bleeding-related Complications After Kidney Biopsy in Patients with Systemic Lupus Erythematosus
Eun Song Kang¹, Ji Seon Oh², Soo Min Ahn¹, Yong Gil Kim¹, Chang-Keun Lee¹, Bin Yoo³ and Seokchan Hong³, ¹Asan Medical Center, Seoul, Republic of Korea, ²Asan Medical Center, Ulsan, Republic of Korea, ³Asan Medical Center, Seoul, South Korea
Background/Purpose: Kidney biopsy is essential for the diagnosis and classification of lupus nephritis in patients with systemic lupus erythematosus (SLE). Even though the risk of…
Abstract Number: 1423 • ACR Convergence 2021
Ability of Soluble Immune Mediators and SLE-associated Autoantibody Specificities to Forecast Transition to Classified SLE and Inform a Lupus Classification Risk Immune Index
Melissa Munroe¹, Rufei Lu², Timothy Gross¹, George Tsokos³, Michael Keith⁴, John Harley⁵ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, OUHSC, Oklahoma City, OK, ³BIDMC, Boston, MA, ⁴Inova, Arlington, VA, ⁵US Department of Veterans Affairs Medical Center, Cincinnati, OH
Background/Purpose: SLE is a chronic autoimmune disease driven by immune dysregulation. We have previously identified patterns of disordered immunity present prior to and concurrent with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].